31
Jul
Wockhardt Ltd, a global pharmaceutical and biotechnology company, is aiming to turnaround its business operations by restructuring its US business, partnering with Serum for UK vaccine manufacturing, and conducting research in novel antibiotics. Q4FY23 saw 7% Yo-Y revenue growth and a three-fold jump in EBITDA to Rs. 47 crore. Wockhardt is restructuring its US operations, shutting down its Morton Grove manufacturing facility and transferring it to contract manufacturing organizations. The company aims to maintain a 40% gross margin and manufacture few higher-margin products through third-party manufacturing. Wockhardt is a leading R&D company with comprehensive antibiotic drug discovery programs, including Emrok,…
